GO
Loading...

Enter multiple symbols separated by commas

Search results for "LLY"

REFINE RESULTS

SEARCH RESULTS

About 33 results. Sort By: Date | Relevance
Financials, economy & Rite Aid lead trades to go

What the "Halftime Report" traders are watching during the second half.
Source: CNBC.com | By: Stephanie Landsman
Trading tech stocks: 5 plays on big movers

"Fast Money" traders discussed how to play some of the day's technology movers, including Alibaba and Hewlett-Packard.
Source: CNBC.com | By: Jacob Pramuk
Your first trade for Thursday

The "Fast Money" traders give their final trades of the day.
Source: CNBC.com | By: Stephanie Landsman
Four trades to go before the closing bell

The "Halftime Report" traders give their trades for the second half.
Source: CNBC.com | By: Bree Kelly
The travel trade: 4 vacation stocks to buy

"Fast Money" traders discussed how to play what is expected to be the busiest summer ever for U.S. airlines.
Source: CNBC.com | By: Jacob Pramuk
Your first trade for Tuesday

The "Fast Money" traders give their final trades of the day.
Source: CNBC.com | By: Michael Newberg
Retail stocks top Halftime's trades to go

The "Halftime Report" traders give their trades for the second half.
Source: CNBC.com | By: Bree Kelly
FDA warns on newer class of diabetes drugs

The agency warned that certain type 2 diabetes drugs may cause high levels of blood acid that could require hospitalization.
Source: Reuters
UPDATE 1-U.S. FDA warns on newer class of type 2 diabetes drugs

May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The FDA said its Adverse Event Reporting System database...
Source: Reuters
U.S. FDA warns on newer class of type 2 diabetes drugs

May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may a cause dangerously high levels of blood acids that could require hospitalization. They include AstraZeneca's Farxiga, J&J's Invokana and...
Source: Reuters